Bard splashes out $250m on hypothermia firm Medivance; spending cuts help Q3 growth
This article was originally published in Clinica
Executive Summary
CR Bard is bulking up its trauma offering by agreeing to acquire Medivance, the leader in the therapeutic hypothermia market, for around $250m. Bard CEO Timothy Ring described the sector as "an emerging and growing space" that is expanding at a double-digit rate.